Management of atrophic maxilla in severe osteoporosis treated with bisphosphonates: a case report.
Studies investigating whether osteoporosis is a risk factor for using implants have revealed no correlation between possible implant failure and the severity of osteoporosis. However, osteoporotic patients frequently require bone regeneration techniques, because they do not fulfil optimum conditions for implant placement owing to the diminished bone structure and rapid resorption of the alveolar bone. We present a successful case of advanced implant therapy using platelet-rich plasma in a patient with severe osteoporosis who had been previously treated with bisphosphonates. We are not aware that this technique has been previously described in literature.
Torres
Jesús
J
Department of Health Sciences III, Faculty of Health Sciences, Rey Juan Carlos University.Madrid, Spain. jesus.torres@urjc.es
Tamimi
Faleh
F
García
Ignacio
I
Cebrian
Jose Luis
JL
López-Cabarcos
Enrique
E
Lopez
Antonio
A
D019386:Alendronate / Q000627:therapeutic use; D016301:Alveolar Bone Loss / Q000601:surgery; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001861:Bone Regeneration; D016025:Bone Transplantation / Q000379:methods*; D003758:Dental Implantation, Endosseous; D005260:Female; D006801:Humans; D008439:Maxillary Diseases / Q000188:drug therapy / Q000601:surgery*; D008443:Maxillary Sinus / Q000601:surgery*; D008875:Middle Aged; D013516:Oral Surgical Procedures, Preprosthetic / Q000379:methods*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000601:surgery*; D053657:Platelet-Rich Plasma
D050071:Bone Density Conservation Agents; D019386:Alendronate